|Location:||Kingston upon Hull|
|Funding for:||UK Students|
|Funding amount:||Not Specified|
|Placed On:||11th June 2021|
|Closes:||2nd July 2021|
About this project
This exciting project funded by Bowel Research UK will investigate the use of clinically relevant targeted therapies as potential novel radiotherapy sensitisers in low oxygen (hypoxia) in colorectal cancer. Colorectal cancer accounts for over 10% of worldwide cancer diagnoses, with high incidence and mortality, and the presence of regions of hypoxia in tumours remain a clear obstacle in treatment for this disease.
You will join a growing and experienced research team led by Dr Isabel Pires, who has published extensively on the field of tumour hypoxia and radiobiology. This project will be closely aligned to the Adaptive Radiotherapy PhD studentship cluster at the University of Hull (also led by Dr Pires), where you will have the opportunity to engage with experts in the field of radiotherapy, molecular imaging, and clinical oncology, including the project co-supervisor Dr Rajarshi Roy, who is a Consultant Clinical Oncologist at Hull University Teaching Hospitals NHS Trust. Furthermore, this project will involve as collaborators leading academics from the University of Oxford and the University of Copenhagen.
We are looking for a highly motivated, enthusiastic, detail-oriented candidate who will have a solid knowledge base and laboratory experience in cell biology and molecular biology, and, ideally, knowledge on cancer biology and relevant laboratory experience. You must also be willing to work in a multi-disciplinary project and research environment.
About the research group
The PI and primary supervisor, Dr Isabel Pires, is a Lecturer in Biomedical Science at the University of Hull. Dr Pires’ lab is focused on the understanding of tumour hypoxia biology and its implication for tumourigenesis, therapy, and metastatic spread.
Dr Rajarshi Roy is a Consultant Clinical Oncologist at Hull University Teaching Hospitals NHS Trust and specialises in the treatment of Colorectal and Upper GI cancers and cancers of unknown primary origin. Our collaborators Dr. Marie Kveiborg (University of Copenhagen) and Professor Ester Hammond (University of Oxford) will also provide additional expertise and support to the project.
Contact Dr Isabel Pires for more information about this project.
The successful applicant will receive a fee waiver and a maintenance grant / stipend for three years, which covers the research period of the PhD. The fee waiver for 21/22 is £4500 (Home fee) and the maintenance grant is £15609. This rises each year in line with the UKRI’s recommended stipend allowance.
Eligibility and entry requirements
Applicants should have either a minimum of 2:1 undergraduate degree Biomedical Science, Cancer Biology, Biochemistry, or a related discipline with relevant experience, or have a Masters-level qualification in a relevant discipline. Experience in cancer biology laboratory techniques is desirable, but other relevant experience may also be considered.
This opportunity comes with a Home fee waiver only.
How to apply
For details on eligibility criteria and information about how to apply, please visit the University of Hull website.
Type / Role: